The RASolute 302 study of daraxonrasib was “the single biggest study presentation” at ASCO 2026, according to Sivraj Muralikrishnan, MD. In an expert-led review of pivotal clinical trial data ...
Jeff Cape, a Blue Faery volunteer and HCC caregiver, shares why patient voices matter at ASCO and what he wishes every cancer patient knew. New ASCO data show a TNBC drug combo works for nearly all ...
Grade 3 or higher TRAEs occurred in 73.7% of patients with HCC who received camrelizumab plus rivoceranib and TACE vs 28.7% who received TACE alone. Atebimetinib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results